A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.

Trial Details

NCT ID

NCT06096779

Phase

PHASE2

Sponsor

Genentech, Inc.

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

Atezolizumab
Bevacizumab

Locations (sample)

Tucson, Arizona, United States|32.22174,-110.92648
La Jolla, California, United States|32.84727,-117.2742
Los Angeles, California, United States|34.05223,-118.24368
Newport Beach, California, United States|33.61891,-117.92895
Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the…
Disease that is not amenable to curative surgical and/or locoregional therapies
No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →